Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: OPK stock price vs VRTX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VRTX's multiple
Needs VRTX P/S.
Implied fair value · at OPK's multiple
Needs OPK P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: OPK FY 2025 (ended Dec 31, 2025) · VRTX FY 2025 (ended Dec 31, 2025).
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
OPKO Health, Inc. · implied price per share
Bear
-$1.74
Base
-$2.04
Bull
-$2.35
VERTEX PHARMACEUTICALS INC / MA · implied price per share
Bear
$149.69
Base
$176.10
Bull
$202.52
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.54x
0.22x
Net debt / EBITDA
Leverage against operating earnings
-3.43x
-0.52x
Cash and equivalents
Liquid reserves on the balance sheet
$368.94M
$6.61B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMARIN CORP PLC\UK
OPK vs AMRN
Sarepta Therapeutics, Inc.
OPK vs SRPT
Amphastar Pharmaceuticals, Inc.
OPK vs AMPH
SUPERNUS PHARMACEUTICALS, INC.
OPK vs SUPN
Harmony Biosciences Holdings, Inc.
OPK vs HRMY
AMGEN INC
OPK vs AMGN
Gilead Sciences, Inc.
OPK vs GILD
BIOGEN INC.
OPK vs BIIB
Moderna, Inc.
OPK vs MRNA
Illumina, Inc.
OPK vs ILMN
$687.93M
$4.06B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
Price unavailable
